FUJIFILM Diosynth Biotechnologies Launches its Apollo Mammalian Expression Platform
![](/46/pdcnewsitem/03/37/44/MChZh6Q2fIlh1Ax.jpg)
FUJIFILM Diosynth Biotechnologies has launched Apollo — its new mammalian expression platform.
The platform is designed to create a robust ‘manufacturing-ready’ cell line and consists of four key components: a new CHO DG44-derived host cell line; a novel expression vector; a cell line development process, utilising state-of-the-art screening technologies and optimised media and feed components. FUJIFILM Diosynth Biotechnologies has demonstrated that this combination leads to a high producing recombinant cell line, which can be used for pre-clinical material through to commercial production, and delivers titers up to 3 g/L before subsequent optimisation.
In addition to high productivity, Apollo also offers robustness and speed to clinic for customers, and can be used throughout the entire product lifecycle. Using transfectant pools, the Apollo platform enables supply of representative material within 10 weeks of receiving a gene sequence, and a manufacturing-ready clonal cell line in 25 weeks from transfection. The platform has low regulatory risk and uses a host cell line with proven track record.
Dr Mark Carver, Senior VP Research, Development & Innovation, FUJIFILM Diosynth Biotechnologies said: “This is an exciting addition to our portfolio of advanced technology solutions for the manufacture of therapeutic proteins. It reflects the excellent work carried out by our team of scientists using state of the art predictive screening and high throughput approaches to create a high quality cell line development platform. We believe the platform has great potential — early media optimisation indicates we can exceed 5 g/L”.
He added: “This development is the latest step in the strategic expansion of our cell culture offering and builds on our 15-year track record in this space. Last year we initiated operation of our new MCC facility at our UK site, and additional 2000-L bioreactors are planned to be installed at both US and UK sites in early 2015. Our Apollo capability, together with these capacities, allows us to offer a ‘gene to GMP’ service for our customers”.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance